10-K: BioMarin Reports $2.9 Billion in Revenue for 2024, Driven by VOXZOGO Expansion

BioMarin achieved $2.9 billion in total revenues in 2024, fueled by VOXZOGO's growth and pipeline advancements, while implementing a new corporate strategy focused on innovation, growth, and value commitment.

Summary

• BioMarin Pharmaceutical Inc. reported total revenues of $2.9 billion for 2024.
• VOXZOGO contributed significantly to the revenue growth, with ongoing expansion efforts.
• The company is advancing VOXZOGO for conditions beyond achondroplasia, including hypochondroplasia, idiopathic short stature, Noonan syndrome, Turner syndrome, and SHOX deficiency.
• BioMarin is focusing on sustained growth of its Enzyme Therapies portfolio, including ALDURAZYME, BRINEURA, NAGLAZYME, PALYNZIQ, and VIMIZIM.
• The company is prioritizing the U.S., Germany, and Italy for ROCTAVIAN commercialization.
• An updated commercial organizational model will be structured around three business units: Skeletal Conditions, Enzyme Therapies, and ROCTAVIAN, starting in 2025.
• A strategic portfolio assessment of research and development programs was completed to identify programs with the strongest scientific merit and commercial potential.
• The company initiated the first-in-human study of BMN 333 in January 2025, a longer-acting CNP for multiple growth disorders.
• Dosing began in December 2024 for the multiple-ascending dose phase of the first-in-human study of BMN 349, an oral therapeutic for liver disease associated with Alpha-1 Antitrypsin Deficiency.
• Enrollment was completed in late 2024 for the first and second dose cohorts of BMN 351, a next-generation oligonucleotide for Duchenne Muscular Dystrophy (DMD).

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both positive financial results and strategic initiatives, as well as acknowledging risks and challenges. The overall tone is cautiously optimistic.

Positives

• VOXZOGO is experiencing strong demand and driving revenue growth.
• The company has a diverse workforce, with significant representation of women and minorities.
• BioMarin has a proven track record of innovation with eight commercial therapies.
• The company is expanding its pipeline with new clinical-stage programs.
• BioMarin has a new corporate strategy focused on innovation, growth, and value commitment.

Negatives

• Generic versions of KUVAN are available, negatively impacting revenues.
• The company faces intense competition from other pharmaceutical companies.
• The company is subject to ongoing regulatory requirements and potential penalties for non-compliance.
• The company has incurred substantial indebtedness that may decrease business flexibility.
• The company has experienced increased employee turnover.

Risks

• Failure to obtain regulatory approval for product candidates could hinder revenue generation.
• Inadequate coverage and reimbursement for products by third-party payers could limit market viability.
• Competition from other pharmaceutical companies and generic versions of products could reduce market share.
• Manufacturing issues or supply interruptions could disrupt product availability.
• International operations are subject to currency risks and regulatory complexities.
• Failure to protect intellectual property could lead to loss of competitive advantage.
• Government healthcare reforms could increase costs and affect revenues.
• Cybersecurity incidents could disrupt operations and compromise sensitive data.
• Macroeconomic conditions could adversely affect the business and financial results.

Future Outlook

BioMarin plans to expand VOXZOGO for additional indications, drive sustained growth of its Enzyme Therapies portfolio, and focus on the U.S., Germany, and Italy for ROCTAVIAN commercialization. The company also expects to continue to contract with outside service providers for certain manufacturing services, including drug substance, drug product, and packaging operations for its products.

Management Comments

• In 2024, we achieved $2.9 billion in total revenues, including a significant contribution from our ongoing expansion of VOXZOGO, and we continued making important advancements in our product development pipeline.
• In the first half of 2024, we focused on value creation through working to accelerate growth, optimize efficiencies and drive operational excellence, including progress in executing on key strategic priorities first outlined in January 2024.
• In September 2024, we held an Investor Day, during which we provided an overview of our new corporate strategy focused on innovation, growth, and value commitment.

Industry Context

BioMarin operates in the highly competitive biopharmaceutical industry, facing competition from both large pharmaceutical companies and smaller biotechnology companies. The company's success depends on its ability to develop and commercialize innovative therapies for rare genetic diseases, navigate the regulatory landscape, and secure adequate reimbursement for its products.

Comparison to Industry Standards

• BioMarin's focus on rare genetic diseases aligns with a growing trend in the biopharmaceutical industry towards developing treatments for niche patient populations.
• The company's revenue growth in 2024 reflects the increasing demand for innovative therapies for rare diseases.
• BioMarin's R&D spending is consistent with industry averages for biotechnology companies focused on drug development.
• The company's commercialization strategy for ROCTAVIAN, focusing on key markets, is a common approach for gene therapy products.
• Competitors in the achondroplasia market include Ascendis Pharma A/S and QED Therapeutics, Inc.
• Competitors in the hemophilia A market include Bayer AG, CSL Behring, Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Management Changes

Corporate Governance

Legal Proceedings

• Shareholder derivative actions filed in the Delaware Court of Chancery were voluntarily dismissed without prejudice after a settlement was not approved by the Court.

Stakeholder Impact

• Shareholders: The company's financial performance and strategic initiatives are likely to influence shareholder value.
• Employees: Workforce reductions and organizational changes may impact employee morale and job security.
• Patients: Continued development and commercialization of therapies for rare diseases will benefit patients and their families.
• Customers: The company's focus on key markets and product expansion may affect product availability and access.
• Suppliers: The company's reliance on single-source suppliers and contract manufacturers creates potential supply chain risks.

Next Steps

• Continue advancing VOXZOGO for additional indications.
• Drive sustained growth of the Enzyme Therapies portfolio.
• Focus on the U.S., Germany, and Italy for ROCTAVIAN commercialization.
• Implement the updated commercial organizational model.
• Continue to invest in research and development programs.

Key Dates

Keywords

VOXZOGO, BioMarin, revenues, ROCTAVIAN, pharmaceutical, clinical trials, product development, manufacturing, regulatory approval, intellectual property